Kiniksa Pharmaceuticals International (KNSA) EBT (2017 - 2026)

Kiniksa Pharmaceuticals International's EBT history runs 10 years deep, the most recent figure standing at $32.7 million for Q1 2026.

• Quarterly EBT rose 109.96% year-over-year to $32.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.2 million (up 365.6% YoY) and the FY2025 annual result came in at $86.1 million, up 1221.88% from the prior year.
• EBT was $32.7 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $20.5 million in the prior quarter.
• Across five years, EBT topped out at $46.7 million in Q3 2022 and bottomed at -$88.3 million in Q4 2022.
• A 5-year average of -$3.8 million and a median of -$1.2 million in 2023 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT plunged 118.19% — and 2025, when it soared 892.93%.
• Kiniksa Pharmaceuticals International's EBT stood at -$88.3 million in 2022, then advanced by 18.38% to -$72.0 million in 2023, then surged by 115.96% to $11.5 million in 2024, then surged by 78.22% to $20.5 million in 2025, then jumped by 59.47% to $32.7 million in 2026.
• Business Quant data shows KNSA's EBT at $32.7 million in Q1 2026, $20.5 million in Q4 2025, and $27.2 million in Q3 2025.